Comprehensive academic textbook chapter writing system for medical/scientific content. Use when the user wants to: (1) Write a full textbook chapter (5,000-15,000 words) on any medical/scientific topic, (2) Generate a detailed table of contents with section word counts, (3) Research topics via PubMed MCP and compile 20-30 references, (4) Write section-by-section with proper citations in Vancouver format, (5) Create publishable academic content with Eric Topol-inspired voice and authentic human prose, (6) Get approval at TOC stage before writing begins, (7) Export well-structured chapters for textbook publication.
Transform topics into publishable textbook chapters with comprehensive research, proper citations, and human-sounding academic prose.
This skill creates full-length academic textbook chapters (5,000-15,000 words) through an agentic workflow:
When user provides topic:
Clarify scope:
Research via PubMed MCP:
Use PubMed:search_articles for:
- Main topic + "review" (find reviews)
- Main topic + "clinical trial" (find trials)
- Main topic + "guideline" (find guidelines)
- Main topic + "meta-analysis" (find syntheses)
Compile reference library:
Report to user: "I've searched PubMed and compiled [N] key references including:
Ready to generate table of contents?"
Generate structured TOC with word allocations:
# [Chapter Title]
## 1. Introduction (~500 words)
- Opening hook (clinical scenario)
- Scope and importance
- Chapter overview
## 2. [Historical Context / Background] (~800 words)
- Evolution of understanding
- Key milestones
- Current landscape
## 3. [Core Topic Area 1] (~1,500 words)
### 3.1 [Subtopic A]
### 3.2 [Subtopic B]
### 3.3 [Subtopic C]
## 4. [Core Topic Area 2] (~1,500 words)
### 4.1 [Subtopic A]
### 4.2 [Subtopic B]
## 5. [Evidence Review / Clinical Data] (~2,000 words)
### 5.1 Landmark Trials
### 5.2 Meta-analyses
### 5.3 Real-world Data
## 6. [Practical Applications / Clinical Pearls] (~1,000 words)
### 6.1 [Application A]
### 6.2 [Application B]
## 7. [Controversies / Ongoing Debates] (~500 words)
## 8. Future Directions (~400 words)
## 9. Conclusions (~300 words)
- Key takeaways
- Practice implications
## References
CRITICAL: WAIT FOR USER APPROVAL
Present TOC and ask: "Here's the proposed structure totaling ~[X] words. Please review and:
After TOC approval, write each section following this pattern:
references/writing-style.md strictly## [Section Title]
[Opening sentence that grounds reader - specific, concrete, not abstract claims]
[Body paragraphs with citations. Each major claim cited. Mix of sentence lengths. No AI tells.]
[Transition to next section or closing thought]
**Citations used in this section:** [1] Author et al., Journal Year; [2] ...
In-text: Sequential numbers [1], [2], [1,3], [4-6]
Reference list format:
1. Author AA, Author BB, Author CC. Title of article. Journal Abbrev. Year;Volume(Issue):Pages. doi:xxx
After all sections approved:
Merge sections - Ensure smooth transitions
Number citations - Sequential through entire chapter
Generate reference list - Vancouver format, numbered
Format check:
Present final chapter:
# [Chapter Title]
[Full content with numbered citations]
## References
1. [Reference 1]
2. [Reference 2]
...
---
Total words: X,XXX
Total references: XX
NEVER use these AI tells:
ALWAYS:
Vocabulary swaps:
Tier 1 (Highest):
Tier 2 (Specialty):
Tier 3 (Field-specific):
| Chapter Length | Minimum References |
|---|---|
| 5,000 words | 15-20 |
| 8,000 words | 20-30 |
| 12,000 words | 30-40 |
| 15,000 words | 40-50 |
User: "Write a textbook chapter on SGLT2 inhibitors in heart failure"
Response: "I'll create a textbook chapter on SGLT2 inhibitors in heart failure. First, let me clarify:
While you answer, I'll start searching PubMed for key references including DAPA-HF, EMPEROR-Reduced, and recent meta-analyses."
[Use PubMed:search_articles]
Response after research: "I've compiled 28 key references from NEJM (6), Lancet (4), JACC (8), Circulation (5), and EHJ (5).
Here's the proposed structure:
Total: ~8,000 words | References: 28
[Approve] [Modify] [Regenerate]"
Response after section completion: "## 3. Clinical Evidence
The clinical development of SGLT2 inhibitors in heart failure followed an unexpected path. Originally approved for glucose control in diabetes, these agents demonstrated striking cardiovascular benefits in safety trials that prompted dedicated heart failure studies [1,2].
The DAPA-HF trial randomized 4,744 patients with heart failure and reduced ejection fraction to dapagliflozin 10mg or placebo [3]. Over a median 18.2 months, dapagliflozin reduced the primary composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65-0.85) [3]. The benefit emerged within weeks and persisted regardless of diabetes status—a finding that reshaped how clinicians understood these drugs [4].
[Continues for ~800 words with 8-10 citations]
Section word count: 823 Citations: [1-10]
Ready to proceed to Section 3.2 (EMPEROR-Reduced)? [Continue] [Revise this section]"
Final chapter delivered as:
# [Chapter Title]
**Author:** [User name if provided]
**Word Count:** X,XXX
**References:** XX
---
[Full chapter content with [numbered] citations]
---
## References
1. [Full Vancouver-format reference]
2. [Full Vancouver-format reference]
...